Connect with us

Coronavirus Outbreak

Clinical Trials Of Sputnik V Coronavirus Vaccine To Begin This Month In Countries Including India

Kirill Dmitriev, CEO of the Russian Direct Investment Fund (RDIF) told that clinical trials of Sputnik V vaccine for coronavirus will begin in Saudi Arabia, United Arab Emirates (UAE), the Philippines, India and Brazil

Highlights
  • Sputnik V, a human adenoviral vector vaccine, fights COVID-19: Researchers
  • Phase I-II clinical trials of Sputnik V showed no serious adverse events
  • Sputnik V has higher level of virus-neutralizing antibodies: RDIF

Moscow: The clinical trials of Sputnik V vaccine for coronavirus will be held this month in several countries including India, confirmed Kirill Dmitriev, CEO of the Russian Direct Investment Fund (RDIF) on Monday (September 7). Kirill Dmitriev told Sputnik that the clinical trials in Saudi Arabia, United Arab Emirates (UAE), the Philippines, India and Brazil will begin this month.

“The post-registration studies involving more than 40,000 people started in Russia on August 26, before AstraZeneca has started its Phase 3 trial in the US with 30,000 participants. Clinical trials in Saudi Arabia, United Arab Emirates (UAE), the Philippines, India and Brazil will begin this month. The preliminary results of the Phase 3 trial will be published in October-November 2020,” said Kirill Dmitriev.

Also Read: Widespread COVID-19 Vaccinations Not Expected Until Mid-2021: World Health Organization

Russia was in close dialogue with the Indian government and the leading drug manufactures of India regarding the localization of production of Sputnik V vaccine in India.

On August 11, the Sputnik V vaccine developed jointly by RDIF and the Gamaleya National Research Center of Epidemiology and Microbiology was registered by the Ministry of Health of Russia and became the world’s first registered vaccine against COVID-19.

According to Russian researchers, Sputnik V is a human adenoviral vector vaccine which fights against coronavirus disease.

India has historically been a very important partner of Russia. India is one of the leading countries in production. Around 60 percent of all the vaccines in the world are produced in India. We are in close dialogue with the corresponding ministries and the India government and the leading manufacturer of the country regarding localisation of production of Sputnik V vaccine in India. And we have achieved certain agreements with the leading companies, Kirill Dmitriev said earlier in response to an ANI query on the talks between India and the Russian government on Sputnik V vaccine.

Also Read: Minimal SARS-CoV-2 Diversity Suggests Global Vaccine Is Feasible: Study

“We do recognise India and its potential to become one of the support for the production of the vaccine not only in Indian markets but for other countries too. We very much appreciate the well- balanced approach expressed by the Indian partners as from the very beginning they started asking questions how our vaccine works and we appreciate it that they did not try to attack our vaccine but try to understand it,” Kirill Dmitriev adding that their (India’s) desire to understand our vaccine got to realize that their approach based on the human adenoviral vaccine platform is the most reasonable approach.

On September 4, a medical journal The Lancet has published the results of clinical trials of Phase I-II of the Russian vaccine demonstrating its safety and efficacy.

Also Read: Russian COVID-19 Vaccine Safe, Induces Antibody Response In Small Trials: Lancet Study

Phase I-II clinical trials of Sputnik V showed no serious adverse events (SAE, Grade 3) for any of the criteria, while the incidence of serious adverse events for other candidate vaccines ranged from 1 per cent to 25 per cent, RDIF press note stated.

“In 100 per cent of participants in the clinical trials, Sputnik V generated a stable humoral and cellular immune response. The level of virus-neutralizing antibodies of volunteers vaccinated with Sputnik V was 1.4-1.5 times higher than the level of antibodies of patients who had recovered from COVID-19,” RDIF press note further read.

Also Read: United States Of America Backs Out From Global Effort To Develop, Distribute COVID-19 Vaccine

(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.) 

NDTV – Dettol Banega Swasth India campaign is an extension of the five-year-old Banega Swachh India initiative helmed by Campaign Ambassador Amitabh Bachchan. It aims to spread awareness about critical health issues facing the country. In wake of the current COVID-19 pandemic, the need for WASH (WaterSanitation and Hygiene) is reaffirmed as handwashing is one of the ways to prevent Coronavirus infection and other diseases. The campaign highlights the importance of nutrition and healthcare for women and children to prevent maternal and child mortality, fight malnutrition, stunting, wasting, anaemia and disease prevention through vaccines. Importance of programmes like Public Distribution System (PDS), Mid-day Meal Scheme, POSHAN Abhiyan and the role of Aganwadis and ASHA workers are also covered. Only a Swachh or clean India where toilets are used and open defecation free (ODF) status achieved as part of the Swachh Bharat Abhiyan launched by Prime Minister Narendra Modi in 2014, can eradicate diseases like diahorrea and become a Swasth or healthy India. The campaign will continue to cover issues like air pollutionwaste managementplastic banmanual scavenging and sanitation workers and menstrual hygiene.  

World

24,20,23,922Cases
20,36,06,535Active
3,34,95,808Recovered
49,21,579Deaths
Coronavirus has spread to 195 countries. The total confirmed cases worldwide are 24,20,23,922 and 49,21,579 have died; 20,36,06,535 are active cases and 3,34,95,808 have recovered as on October 21, 2021 at 4:33 am.

India

3,41,27,450 18,454Cases
1,78,831 733Active
3,34,95,808 17,561Recovered
4,52,811 160Deaths
In India, there are 3,41,27,450 confirmed cases including 4,52,811 deaths. The number of active cases is 1,78,831 and 3,34,95,808 have recovered as on October 21, 2021 at 2:30 am.

State Details

State Cases Active Recovered Deaths
Maharashtra

65,96,645 1,825

29,333 1,075

64,27,426 2,879

1,39,886 21

Kerala

48,79,790 11,150

83,333 2,476

47,69,373 8,592

27,084 82

Karnataka

29,84,484 462

9,103 26

29,37,405 479

37,976 9

Tamil Nadu

26,90,633 1,170

14,058 268

26,40,627 1,418

35,948 20

Andhra Pradesh

20,61,810 523

5,566 88

20,41,924 608

14,320 3

Uttar Pradesh

17,10,058 11

112 6

16,87,048 17

22,898

West Bengal

15,82,813 867

7,491 63

15,56,315 795

19,007 9

Delhi

14,39,466 25

310 12

14,14,066 37

25,090

Odisha

10,36,532 559

4,387 106

10,23,849 451

8,296 2

Chhattisgarh

10,05,735 34

185 3

9,91,979 36

13,571 1

Rajasthan

9,54,393 1

38 0

9,45,401 1

8,954

Gujarat

8,26,340 14

176 9

8,16,077 22

10,087 1

Madhya Pradesh

7,92,709 9

82 3

7,82,104 6

10,523

Haryana

7,71,116 15

133 7

7,60,934 8

10,049

Bihar

7,26,036 3

30 12

7,16,345 15

9,661

Telangana

6,69,556 191

3,968 28

6,61,646 162

3,942 1

Assam

6,07,427 308

3,610 25

5,97,859 282

5,958 1

Punjab

6,02,113 32

232 16

5,85,331 15

16,550 1

Jharkhand

3,48,486 25

142 14

3,43,209 11

5,135

Uttarakhand

3,43,773 8

176 1

3,36,199 6

7,398 1

Jammu And Kashmir

3,31,299 78

800 3

3,26,070 80

4,429 1

Himachal Pradesh

2,21,936 110

1,394 46

2,16,815 64

3,727

Goa

1,77,706 47

597 23

1,73,755 70

3,354

Puducherry

1,27,521 42

461 29

1,25,208 71

1,852

Manipur

1,22,970 71

1,360 2

1,19,706 66

1,904 3

Mizoram

1,15,207 741

10,263 505

1,04,548 1,243

396 3

Tripura

84,351 2

95 7

83,440 9

816

Meghalaya

83,158 79

761 21

80,958 58

1,439

Chandigarh

65,312 2

24 1

64,468 3

820

Arunachal Pradesh

55,043 12

138 7

54,625 19

280

Sikkim

31,800 17

175 6

31,232 22

393 1

Nagaland

31,659 18

255 8

30,728 10

676

Ladakh

20,886 3

34 0

20,644 3

208

Dadra And Nagar Haveli

10,676

2 2

10,670 2

4

Lakshadweep

10,365

0 0

10,314

51

Andaman And Nicobar Islands

7,646

7 1

7,510 1

129

Coronavirus Outbreak: Full CoverageTesting CentresFAQs
 

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Highlights From The 12-Hour Telethon

Leaving No One Behind

Mental Health

Environment

Join Us